Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation

References

• Ahmed T, Gilani A-U-H, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM. 2015. Berberine and neurodegeneration: a review of literature. Pharmacol Rep. 67(5):970–979.
   PubMed Web of Science ®Google Scholar
• Alvarez-Diez TM, Zheng J. 2004. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol. Chem Res Toxicol. 17(2):150–157.
   PubMed Web of Science ®Google Scholar
• Bellevue FHI, Woster PM, Edwards DJ, et al. 1997. Synthesis and biological evaluation of 6′,7′-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450 3A4. Bioorg Med Chem Lett. 7:2593–2598.
   Web of Science ®Google Scholar
• Boonruang S, Prakobsri K, Pouyfung P, Srisook E, Prasopthum A, Rongnoparut P, Sarapusit S. 2017. Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea. J Enzyme Inhib Med Chem. 32(1):1136–1142.
   PubMed Web of Science ®Google Scholar
• Bornheim LM, Everhart ET, Li J, Correia MA. 1993. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol. 45(6):1323–1331.
   PubMed Web of Science ®Google Scholar
• Brady JF, Ishizaki H, Fukuto JM, Lin MC, Fadel A, Gapac JM, Yang CS. 1991. Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem Res Toxicol. 4(6):642–647.
   PubMed Web of Science ®Google Scholar
• Cai Y, Baer-Dubowska W, Ashwood-Smith MJ, Ceska O, Tachibana S, DiGiovanni J. 1996. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem Res Toxicol. 9(4):729–736.
   PubMed Web of Science ®Google Scholar
• Cao J, Zheng L, Ji L, Lu D, Peng Y, Zheng J. 2015. Mechanism-based inactivation of cytochrome P450 2B6 by isoimperatorin. Chem Biol Interact. 226:23–29.
   PubMed Web of Science ®Google Scholar
• Chae A, Shim J, Chun Y. 2008. Mechanism of inhibition of human cytochrome P450 1A1 and 1B1 by piceatannol. Biomol Ther. 16(4):336–342.
   Web of Science ®Google Scholar
• Chan WK, Delucchi AB. 2000. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67(25):3103–3112.
   PubMed Web of Science ®Google Scholar
• Chan WK, Nguyen LT, Miller VP, Harris RZ. 1998. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci. 62(10):PL135–PL142.
   PubMed Web of Science ®Google Scholar
• Chatterjee P, Franklin MR. 2003. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 31(11):1391–1397.
   PubMed Web of Science ®Google Scholar
• Chen X, Dang TT, Facchini PJ. 2015. Noscapine comes of age. Phytochemistry. 111:7–13.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yu J, Wang X, Li H, Mao X, Peng Y, Zheng J. 2019. Characterization of glutathione conjugates derived from reactive metabolites of seven silymarin isomers. Xenobiotica. 49(11):1269–1278.
   PubMed Web of Science ®Google Scholar
• Cholewka-Stafińska M, Polaniak R, Kardas M, Grajek M, Grochowska-Niedworok E. 2017. Interaction of oral form anticancer drugs with grapefruit juice. Pol Merkur Lekarski. 42(247):30–33.
   PubMedGoogle Scholar
• Cui T, Wang Q, Tian X, Zhang K, Peng Y, Zheng J. 2020. Piperine is a mechanism-based inactivator of CYP3A. Drug Metab Dispos. 48(2):123–134.
   PubMed Web of Science ®Google Scholar
• Dai J, Zhang F, Zheng J. 2010. Retrorsine, but not monocrotaline, is a mechanism-based inactivator of P450 3A4. Chem Biol Interact. 183(1):49–56.
   PubMed Web of Science ®Google Scholar
• de Oliveira DM, Ferreira Lima RM, Clarencio J, Velozo E. d S, de Amorim IA, Andrade da Mota TH, Costa SL, Silva FP, El-Bachá RDS. 2016. The classical photoactivated drug 8-methoxypsoralen and related compounds are effective without UV light irradiation against glioma cells. Neurochem Int. 99:33–41.
   PubMed Web of Science ®Google Scholar
• Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. 2002. The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 71(10):1149–1160.
   PubMed Web of Science ®Google Scholar
• Diogo CV, Machado NG, Barbosa IA. 2011. Berberine as a promising safe anti-cancer agent – is there a role for mitochondria? Curr Drug Targets. 12:850–859.
   PubMed Web of Science ®Google Scholar
• Draper AJ, Madan A, Parkinson A. 1997. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys. 341(1):47–61.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Urquhart BL, Proniuk J, Tieu A, Freeman DJ, Arnold JM, Bailey DG. 2017. Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. Pharmacol Res Perspect. 5(5):e00346.
   Web of Science ®Google Scholar
• Ekstrand B, Rasmussen MK, Woll F, Zlabek V, Zamaratskaia G. 2015. In vitro gender-dependent inhibition of porcine cytochrome p450 activity by selected flavonoids and phenolic acids. Biomed Res Int. 2015:387918.
   PubMed Web of Science ®Google Scholar
• Fasinu PS, Gutmann H, Schiller H, James A-D, Bouic PJ, Rosenkranz B. 2013. The potential of Sutherlandia frutescens for herb-drug interaction. Drug Metab Dispos. 41(2):488–497.
   PubMed Web of Science ®Google Scholar
• Franklin MR. 1971. The enzymic formation of methylenedioxyphenyl derivative exhibiting an isocyanide-like spectrum with reduced cytochrome P-450 in hepatic microsomes. Xenobiotica. 1(6):581–591.
   PubMedGoogle Scholar
• Fu Y, Tian X, Han L, Li Y, Peng Y, Zheng J. 2020. Mechanism-based inactivation of cytochrome P450 2D6 by Notopterol. Chem Biol Interact. 322:109053.
   PubMed Web of Science ®Google Scholar
• Gan L-S, Zheng Y-L, Mo J-X, Liu X, Li X-H, Zhou C-X. 2009. Sesquiterpene Lactones from the Root Tubers of Lindera aggregata. J Nat Prod. 72(8):1497–1501.
   PubMed Web of Science ®Google Scholar
• Girennavar B, Jayaprakasha GK, Patil BS. 2007. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J Food Science. 72(8):C417–C421.
   PubMed Web of Science ®Google Scholar
• Goosen TC, Kent UM, Brand L, Hollenberg PF. 2000. Inactivation of cytochrome P450 2B1 by benzyl isothiocyanate, a chemopreventative agent from cruciferous vegetables. Chem Res Toxicol. 13(12):1349–1359.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Waterman MR, Egli M. 2016. Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci. 37(8):625–640.
   PubMed Web of Science ®Google Scholar
• Guo X, Lin D, Li W, Wang K, Peng Y, Zheng J. 2016. Electrophilicities and protein covalent binding of demethylation metabolites of colchicine. Chem Res Toxicol. 29(3):296–302.
   PubMed Web of Science ®Google Scholar
• Guo LQ, Yamazoe Y. 2004. Inhibition of cytochrom P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin. 25(2):129–136.
   PubMed Web of Science ®Google Scholar
• Hadjokas NE, Dai R, Friedman FK, Spence MJ, Cusack BJ, Vestal RE, Ma Y. 2002. Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells. Br J Pharmacol. 136(3):347–352.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. 2011. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 7(3):267–286.
   PubMed Web of Science ®Google Scholar
• He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. 1998. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 11(4):252–259.
   PubMed Web of Science ®Google Scholar
• Hirao H, Chuanprasit P, Cheong YY, Wang X. 2013. How is a metabolic intermediate formed in the mechanism-based inactivation of cytochrome P450 by using 1,1-dimethylhydrazine: hydrogen abstraction or nitrogen oxidation? Chem Eur J. 19(23):7361–7369.
   PubMed Web of Science ®Google Scholar
• Imenshahidi M, Hosseinzadeh H. 2019. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 33(3):504–523.
   PubMed Web of Science ®Google Scholar
• Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. 2004. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos. 32(12):1351–1358.
   PubMed Web of Science ®Google Scholar
• Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. 2005. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. Drug Metab Pharmacokinet. 20(1):34–45.
   PubMedGoogle Scholar
• Jeong H-U, Kwon S-S, Kong TY, Kim JH, Lee HS. 2014. Inhibitory effects of cedrol, β-cedrene, and thujopsene on cytochrome P450 enzyme activities in human liver microsomes. J Toxicol Environ Health Part A. 77(22–24):1522–1532.
   PubMed Web of Science ®Google Scholar
• Ji L, Lu D, Cao J, Zheng L, Peng Y, Zheng J. 2015. Psoralen, a mechanism-based inactivator of CYP2B6. Chem Biol Interact. 240:346–352.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Scott Obac R, Maurer TS. 2007. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab. 8(5):407–447.
   PubMed Web of Science ®Google Scholar
• Kamel A, Harriman S. 2013. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discov Today Technol. 10(1):e177–e189.
   PubMedGoogle Scholar
• Kang A-Y, Young LR, Dingfelder C, Peterson S. 2011. Effects of furanocoumarins from apiaceous vegetables on the catalytic activity of recombinant human cytochrome P-450 1A2. Protein J. 30(7):447–456.
   PubMed Web of Science ®Google Scholar
• Kent UM, Aviram M, Rosenblat M, Hollenberg PF. 2002. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos. 30(6):709–715.
   PubMed Web of Science ®Google Scholar
• Kent UM, Lin H-l, Noon KR, Harris DL, Hollenberg PF. 2006. Metabolism of bergamottin by cytochromes P450 2B6 and 3A5. J Pharmacol Exp Ther. 318(3):992–1005.
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Trager WF. 1998. Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry. 37(38):13184–13193.
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Trager WF. 1998. Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry. 37(28):10047–10061.
   PubMed Web of Science ®Google Scholar
• Korobkova EA. 2015. Effect of natural polyphenols on CYP metabolism: implications for diseases. Chem Res Toxicol. 28(7):1359–1390.
   PubMed Web of Science ®Google Scholar
• Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. 2015. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 161:69–81.
   PubMed Web of Science ®Google Scholar
• Lin H, Kent UM, Hollenberg PF. 2005. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther. 313(1):154–164.
   PubMed Web of Science ®Google Scholar
• Lin H-l, Zhang H, Pratt-Hyatt MJ, Hollenberg PF. 2011. Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene. Drug Metab Dispos. 39(12):2431–2439.
   PubMed Web of Science ®Google Scholar
• Lin H-L, Zhang H, Walker VJ, D'Agostino J, Hollenberg PF. 2017. Heme modification contributes to the mechanism-based inactivation of human cytochrome P450 2J2 by two terminal acetylenic compounds. Drug Metab Dispos. 45(9):990–999.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cui T, Peng Y, Ji M, Zheng J. 2019. Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine. J Biochem Mol Toxicol. 33(2):e22251.
   PubMed Web of Science ®Google Scholar
• Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. 1997. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 99(10):2545–2553.
   PubMed Web of Science ®Google Scholar
• Lu D, Ji L, Zheng L, Cao J, Peng Y, Zheng J. 2016. Mechanism-based inactivation of cytochrome P450 2B6 by isopsoralen. Xenobiotica. 46(4):335–341.
   PubMed Web of Science ®Google Scholar
• Mao X, Hu Z, Wang Q, Zhang N, Zhou S, Peng Y, Zheng J. 2018. Nitidine chloride is a mechanism-based inactivator of CYP2D6. Drug Metab Dispos. 46(8):1137–1145.
   PubMed Web of Science ®Google Scholar
• Mao X, Zhao H, Wang Q, Li H, Yang L, Hu Z, Zhang F, Guo X, Peng Y, Zheng J. 2019. Metabolism-based herb-drug interaction of Corydalis bungeanae Herba with berberine in vitro and in vivo in rats. Biomed Chromatogr. 33(7):e4514.
   PubMed Web of Science ®Google Scholar
• Matsuda H, Morikawa T, Ninomiya K. 2001. Hepatoprotective constituents from Zedoariae Rhizoma: absolute stereostructures of three new carabrane-type sesquiterpenes, curcumenolactones A, B, and C. Bioorg Med Chem. 9:909–916.
   PubMed Web of Science ®Google Scholar
• Moreno RL, Kent UM, Hodge K, Hollenberg PF. 1999. Inactivation of cytochrome P450 2E1 by benzyl isothiocyanate. Chem Res Toxicol. 12(7):582–587.
   PubMed Web of Science ®Google Scholar
• Murray M. 2000. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab. 1(1):67–84.
   PubMed Web of Science ®Google Scholar
• Murray J, Picking D, Lamm A, McKenzie J, Hartley S, Watson C, Williams L, Lowe H, Delgoda R. 2016. Significant inhibitory impact of dibenzyl trisulfide and extracts of Petiveria alliacea on the activities of major drug-metabolizing enzymes in vitro: an assessment of the potential for medicinal plant-drug interactions. Fitoterapia. 111:138–146.
   PubMed Web of Science ®Google Scholar
• Šarić Mustapić D, Debeljak Ž, Maleš Ž, Bojić M. 2018. The inhibitory effect of flavonoid aglycones on the metabolic activity of CYP3A4 enzyme. Molecules. 23(10):2553–2512.
   Web of Science ®Google Scholar
• Ohlsson S, Holm L, Myrberg O, Sundström A, Yue Q-Y. 2008. Noscapine may increase the effect of warfarin. Br J Clin Pharmacol. 65(2):277–278.
   PubMed Web of Science ®Google Scholar
• Orr STM, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, Kalgutkar AS. 2012. Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem. 55(11):4896–4933.
   PubMed Web of Science ®Google Scholar
• Peterson S, Lampe JW, Bammler TK, Gross-Steinmeyer K, Eaton DL. 2006. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem Toxicol. 44(9):1474–1484.
   PubMed Web of Science ®Google Scholar
• Philpot RM, Hodgson E. 1971. A cytochrome P-450-piperonyl butoxide spectrum similar to that produced by ethyl isocyanide. Life Sci. 10(9):503–512.
   Web of Science ®Google Scholar
• Piver B, Berthou F, Dreano Y, Lucas D. 2001. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other nonvolatile red wine components. Toxicol Lett. 125(1–3):83–91.
   PubMed Web of Science ®Google Scholar
• Prasopthum A, Pouyfung P, Sarapusit S, Srisook E, Rongnoparut P. 2015. Inhibition effects of Vernonia cinerea active compounds against cytochrome P450 2A6 and human monoamine oxidases, possible targets for reduction of tobacco dependence. Drug Metab Pharmacokinet. 30(2):174–181.
   PubMed Web of Science ®Google Scholar
• Rendic S, Guengerich FP. 2015. Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol. 28(1):38–42.
   PubMed Web of Science ®Google Scholar
• Rosenborg S, Stenberg M, Otto S, Ostervall J, Masquelier M, Yue Q-Y, Bertilsson L, Eliasson E. 2010. Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clin Pharmacol Ther. 88(3):343–346.
   PubMed Web of Science ®Google Scholar
• Row EC, Brown SA, Stachulski AV, Lennard MS. 2006. Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CYP3A4. Org Biomol Chem. 4(8):1604–1610.
   PubMed Web of Science ®Google Scholar
• Sakaki T, Yasuda K, Nishikawa M, Ikushiro S. 2018. [Metabolism of sesamin and drug-sesamin interaction]. Yakugaku Zasshi. 138(3):357–363.
   PubMed Web of Science ®Google Scholar
• Salminen KA, Meyer A, Imming P, Raunio H. 2011. CYP2C19 progress curve analysis and mechanism-based inactivation by three methylenedioxyphenyl compounds. Drug Metab Dispos. 39(12):2283–2289.
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, et al. 1997. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 25(11):1228–1233.
   PubMed Web of Science ®Google Scholar
• Scordo MG, Melhus H, Stjernberg E, Edvardsson AM, Wadelius M. 2008. Warfarin-noscapine interaction: a series of four case reports. Ann Pharmacother. 42(3):448–455.
   PubMed Web of Science ®Google Scholar
• Seden K, Dickinson L, Khoo S, Back D. 2010. Grapefruit-drug interactions. Drugs. 70(18):2373–2407.
   PubMed Web of Science ®Google Scholar
• Song J-H, Sun D-X, Chen B, Ji D-H, Pu J, Xu J, Tian F-D, Guo L. 2011. Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: implication for clinical drug-drug interactions. J Biosci. 36(5):879–885.
   PubMed Web of Science ®Google Scholar
• Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. 2004. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 32(6):587–594.
   PubMed Web of Science ®Google Scholar
• Sridar C, Kenaan C, Hollenberg PF. 2012. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab Dispos. 40(12):2256–2266.
   PubMed Web of Science ®Google Scholar
• Stupans I, Murray M, Kirlich A, Tuck KL, Hayball PJ. 2001. Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food Chem Toxicol. 39(11):1119–1124.
   PubMed Web of Science ®Google Scholar
• Subehan Zaid SFH, Kadota S, et al. 2007. Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (Foeniculum vulgare): identification and characterization of a mechanism-based inactivator. J Agric Food Chem. 55:10162–10167.
   PubMed Web of Science ®Google Scholar
• Sunaga K, Ohkawa K, Nakamura K, Ohkubo A, Harada S, Tsuda T. 2012. Mechanism-based inhibition of recombinant human cytochrome P450 3A4 by tomato juice extract. Biol Pharm Bull. 35(3):329–334.
   PubMed Web of Science ®Google Scholar
• Taesotikul T, Dumrongsakulchai W, Wattanachai N, Navinpipat V, Somanabandhu A, Tassaneeyakul W, Tassaneeyakul W. 2011. Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab Pharmacokinet. 26(2):154–161.
   PubMed Web of Science ®Google Scholar
• Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K, Urae A, Higuchi S, Sawada Y. 2000. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol. 49(1):49–58.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. 2000. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys. 378(2):356–363.
   PubMed Web of Science ®Google Scholar
• Tegeder I, Bräutigam L, Podda M, Meier S, Kaufmann R, Geisslinger G, Grundmann-Kollmann M. 2002. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen. Clin Pharmacol Ther. 71(3):153–161.
   PubMed Web of Science ®Google Scholar
• Ueng Y-F, Chen C-C, Yamazaki H, Kiyotani K, Chang Y-P, Lo W-S, Li D-T, Tsai P-L. 2013. Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. Drug Metab Pharmacokinet. 28(3):229–238.
   PubMed Web of Science ®Google Scholar
• Usia T, Watabe T, Kadota S, Tezuka Y. 2005. Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. Biol Pharm Bull. 28(6):1021–1024.
   PubMed Web of Science ®Google Scholar
• Usia T, Watabe T, Kadota S, Tezuka Y. 2005. Mechanism-based inhibition of CYP3A4 by constituents of Zingiber aromaticum. Biol Pharm Bull. 28(3):495–499.
   PubMed Web of Science ®Google Scholar
• Usia T, Watabe T, Kadota S, Tezuka Y. 2005. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci. 76(20):2381–2391.
   PubMed Web of Science ®Google Scholar
• von Weymarn LB, Zhang Q-Y, Ding X, Hollenberg PF. 2005. Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis. 26(3):621–629.
   PubMed Web of Science ®Google Scholar
• Wang K, Feng X, Chai L, Cao S, Qiu F. 2017. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 49(2):139–157.
   PubMed Web of Science ®Google Scholar
• Wang K, Gao Q, Zhang T, Rao J, Ding L, Qiu F. 2020. Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions. Drug Metab Rev. 52(2):235–257.
   PubMed Web of Science ®Google Scholar
• Wang X-l, Kong F, Shen T, Young CYF, Lou H-x, Yuan H-q. 2011. Sesquiterpenoids from myrrh inhibit androgen receptor expression and function in human prostate cancer cells. Acta Pharmacol Sin. 32(3):338–344.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Mao X, Zhang Q, Yao T, Peng Y, Zheng J. 2015. Mechanism-based inactivation of CYP2C9 by linderane. Xenobiotica. 45(12):1037–1046.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang K, Sui D, Ouyang Z, Xu H, Wei Y. 2017. Effects of tetrahydroberberine and tetrahydropalmatine on hepatic cytochrome P450 expression and their toxicity in mice. Chem Biol Interact. 268:47–52.
   PubMed Web of Science ®Google Scholar
• Wang K, Zheng L, Peng Y, Song J-e, Zheng J. 2014. Selective and sensitive platform for function-based screening of potentially harmful furans. Anal Chem. 86(21):10755–10762.
   PubMed Web of Science ®Google Scholar
• Wangensteen H, Molden E, Christensen H, Malterud KE. 2003. Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peel. Eur J Clin Pharmacol. 58(10):663–668.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Yamaori S, Kamijo S, Aikawa K, Ohmori S. 2020. In vitro inhibitory effects of Sesamin on CYP4F2 activity. Biol Pharm Bull. 43(4):688–692.
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. 2005. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 4(10):825–833.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Kushihara M, Yamamoto I, Watanabe K. 2010. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol. 79(11):1691–1698.
   PubMed Web of Science ®Google Scholar
• Yan R, Yang Y, Zeng Y, Zou G. 2009. Cytotoxicity and antibacterial activity of Lindera strychnifolia essential oils and extracts. J Ethnopharmacol. 121(3):451–455.
   PubMed Web of Science ®Google Scholar
• Yang A-H, He X, Chen J-X, He L-N, Jin C-H, Wang L-L, Zhang F-L, An L-J. 2015. Identification and characterization of reactive metabolites in myristicin-mediated mechanism-based inhibition of CYP1A2. Chem Biol Interact. 237:133–140.
   PubMed Web of Science ®Google Scholar
• Yang A-H, Zhang L, Zhi D-X, Liu W-L, Gao X, He X. 2018. Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole. Xenobiotica. 48(11):1164–1172.
   PubMed Web of Science ®Google Scholar
• Yoo HH, Lee S-H, Jin C, Kim D-H. 2008. Mechanism-based inactivation of cytochrome P450 3A4 by methylenedioxyphenyl lignans from Acanthopanax chiisanensis. Planta Med. 74(8):822–827.
   PubMed Web of Science ®Google Scholar
• Zhang H, Amunugama H, Ney S, Cooper N, Hollenberg PF. 2011. Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme. Mol Pharmacol. 80(5):839–847.
   PubMed Web of Science ®Google Scholar
• Zhang N, Seguin RP, Kunze KL, Zhang Y-Y, Jeong H. 2013. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy. Drug Metab Dispos. 41(12):2114–2123.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hellum BH, Liang A, Nilsen OG. 2015. Inhibitory mechanisms of human CYPs by three alkaloids isolated from traditional Chinese herbs. Phytother Res. 29(6):825–834.
   PubMed Web of Science ®Google Scholar
• Zheng L, Cao J, Lu D, Ji L, Peng Y, Zheng J. 2015. Imperatorin is a mechanism-based inactivator of CYP2B6. Drug Metab Dispos. 43(1):82–88.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Luan L, Gan L, Zhou C, Wu Y. 2009. Simultaneous determination of three sesquiterpene lactones in Radix Linderae by HPLC. Zhongguo Zhong Yao Za Zhi. 34(21):2777–2780.
   PubMedGoogle Scholar
• Zhong Q, Shi Z, Zhang L, Zhong R, Xia Z, Wang J, Wu H, Jiang Y, Sun E, Wei Y, et al. 2017. The potential of Epimedium koreanum Nakai for herb-drug interaction. J Pharm Pharmacol. 69(10):1398–1408.
   PubMed Web of Science ®Google Scholar